Aldesleukin Completed Phase 2 Trials for Metastatic Melanoma / Melanoma / Skin Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01266603High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
NCT01118091Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
NCT00509288Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
NCT00923195Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
NCT00204581Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
NCT00665470Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
NCT00910650Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
NCT00314106Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma